733 related articles for article (PubMed ID: 16941377)
1. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
2. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
3. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
4. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
5. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Berman JD
Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
[No Abstract] [Full Text] [Related]
6. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
[TBL] [Abstract][Full Text] [Related]
7. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
8. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
9. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
Borrelli P; Imperato A; Murdaca G; Scudeletti M
Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
12. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
13. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
15. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
17. Treatment of leishmaniasis in HIV-positive patients.
Laguna F
Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
Singh GP; Saxena RK; Priyadarshy V
J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
